Indeed, treatment with CD19/IL-12 CAR T cells significantly enhanced the survival of CD19-EL4 tumor-bearing mice vs. treatment with CD19 CAR T cells (75 vs. 0% survival at day 60 after tumor inoculation) (323). This evidence concerns the gene CD19 and neoplasm.